Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159828 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by Axion Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 7
- Study locations
NCT07159828: Active Phase 1 study of Solid Tumor, Adult, sponsored by Axion Bio.
NCT07159828 is a Phase 1 study of Solid Tumor, Adult that is active but no longer recruiting, run by Axion Bio. The registered enrollment target is 52 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07159828, a Phase 1 study of Solid Tumor, Adult, is active but no longer recruiting, sponsored by Axion Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are: * What are the side effects of AXN-2510? * Which is the best tolerated dose of AXN-2510? * How long does AXN-2510 stay in your body? Participants will receive AXN-2510 every 3 weeks. Participants will visit the clinic for checkups and tests several days during the first and third doses, and once every 3 weeks for other doses.
Primary Outcome
A DLT is defined as a toxicity occurring during the DLT observation period
Conditions Studied
Interventions
- BIOLOGICAL AXN-2510
Study Locations (7)
Texas
- Sarah Cannon Research Institute at Mary Crowley - Dallas
- New Experimental Therapeutics (NEXT) Oncology - Houston - Houston
- NEXT Houston - Houston
- New Experimental Therapeutics of San Antonio - NEXT Oncology - San Antonio
- NEXT San Antonio - San Antonio
North Carolina
- Carolina BioOncology - Huntersville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2027-05-15 |
| Phase | Phase 1 |
What the registry record for NCT07159828 still lists
NCT07159828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which AXN-2510 is the first listed.
NCT07159828 lists 7 locations in 3 states (Texas, North Carolina, Virginia).
Frequently Asked Questions
What is clinical trial NCT07159828 about?
NCT07159828 is a clinical study titled "A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors". The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are: * What are the side effects of AXN-2510? * Which is the best tolerated dose of AXN-2510? * How long does AXN-2510 stay in...
What is the current status of trial NCT07159828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-09-15. Estimated completion is 2027-05-15.
What conditions does trial NCT07159828 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT07159828?
The interventions under investigation include: AXN-2510 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07159828?
This trial is sponsored by Axion Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159828 being conducted?
This trial has 7 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07159828's enrollment target sits among peer trials
52 57th of 72 higher than 14 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI